The British pharma is paying CSPC Pharmaceutical $30 million upfront, with $1.74 billion in potential development and sales milestones, to jointly discover and develop two kidney disease candidates based on the latter company's siRNA platform
As the GLP-1 landscape continues to evolve, the goal is no longer simply deciding whether to cover these medicationsbut determining how to maximize their value for both employees and employer-sponsored health plans.
Broad Model Compatibility: Useful in cell lines, tissue preparations, and biochemical assays where researchers need to measure or adjust glutathione status
Place one patch on the body, using one of the locations shown
Food and Drug Administration (2023) Wegovy highlights of prescribing information, The U.S
Pharmacy dispensing and clinical logistics explained simply Coaching plus medication only works if patients can reliably get their prescriptions filled